{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T20:02:10Z","timestamp":1760472130648},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,3,24]],"date-time":"2013-03-24T00:00:00Z","timestamp":1364083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1245\/s10434-013-2878-9","type":"journal-article","created":{"date-parts":[[2013,3,23]],"date-time":"2013-03-23T08:45:35Z","timestamp":1364028335000},"page":"3059-3065","source":"Crossref","is-referenced-by-count":12,"title":["Lung Resistance-Related Protein (LRP) Expression in Malignant Ascitic Cells as a Prognostic Marker for Advanced Ovarian Serous Carcinoma"],"prefix":"10.1245","volume":"20","author":[{"given":"Elizabeth H.","family":"Kerr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecil R.","family":"Stockard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"DellaManna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise K.","family":"Oelschlager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope M.","family":"Amm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isam-Eldin","family":"Eltoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Michael Straughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald J.","family":"Buchsbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Grizzle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lacey R.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,24]]},"reference":[{"key":"2878_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin."},{"key":"2878_CR2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053\u201364.","journal-title":"Am J Pathol."},{"key":"2878_CR3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519\u201329.","journal-title":"N Engl J Med."},{"key":"2878_CR4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/1040-8428(92)90057-W","volume":"12","author":"LJ Goldstein","year":"1992","unstructured":"Goldstein LJ, Pastan I, Gottesman MM. Multidrug resistance in human cancer. Crit Rev Oncol Hematol. 1992;12:243\u201353.","journal-title":"Crit Rev Oncol Hematol."},{"key":"2878_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00689638","volume":"13","author":"G Bradley","year":"1994","unstructured":"Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 1994;13:223\u201333.","journal-title":"Cancer Metastasis Rev."},{"key":"2878_CR6","first-page":"4124","volume":"56","author":"K Taniguchi","year":"1996","unstructured":"Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996;56:4124\u20139.","journal-title":"Cancer Res."},{"key":"2878_CR7","first-page":"3537","volume":"57","author":"M Kool","year":"1997","unstructured":"Kool M, de Hass M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57:3537\u201347.","journal-title":"Cancer Res."},{"key":"2878_CR8","first-page":"2798","volume":"5","author":"HJ Arts","year":"1999","unstructured":"Arts HJ, Katsaros D, de Vries EG, et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res. 1999;5:2798\u2013805.","journal-title":"Clin Cancer Res."},{"key":"2878_CR9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/A:1008004502861","volume":"27","author":"MA Izquierdo","year":"1998","unstructured":"Izquierdo MA, Scheffer GL, Schroeijers AB, et al. Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP. Cytotechnology. 1998;27:137\u201348.","journal-title":"Cytotechnology."},{"key":"2878_CR10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1083\/jcb.103.3.699","volume":"103","author":"NL Kedersha","year":"1986","unstructured":"Kedersha NL, Rome LH, Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol. 1986;103:699\u2013709.","journal-title":"J Cell Biol."},{"key":"2878_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0962-8924(91)90088-Q","volume":"1","author":"L Rome","year":"1991","unstructured":"Rome L, Kedersha N, Chugani D, Unlocking vaults: organelles in search of a function. Trends Cell Biol. 1991;1:47\u201350.","journal-title":"Trends Cell Biol."},{"key":"2878_CR12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1349-7006.2007.00492.x","volume":"98","author":"Y Oda","year":"2007","unstructured":"Oda Y, Ohishi Y, Basaki Y, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP\/MVP and P-glycoprotein expression. Cancer Sci. 2007;98:1020\u20136.","journal-title":"Cancer Sci."},{"key":"2878_CR13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2005.08.050","volume":"100","author":"E Yakirevich","year":"2006","unstructured":"Yakirevich, E, Sabo E, Naroditsky I, et al. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol. 2006;100:152\u20139.","journal-title":"Gynecol Oncol."},{"key":"2878_CR14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/gyno.2000.6105","volume":"81","author":"BA Goff","year":"2001","unstructured":"Goff BA, Paley PJ, Greer BE, et al. Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol Oncol. 2001;81:18\u201324.","journal-title":"Gynecol Oncol."},{"key":"2878_CR15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.1998.5094","volume":"70","author":"BA Goff","year":"1998","unstructured":"Goff BA, Ries JA, Els LP, et al. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol. 1998;70:378\u201385.","journal-title":"Gynecol Oncol."},{"key":"2878_CR16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","volume":"113","author":"K Shield","year":"2009","unstructured":"Shield K, Ackland ML, Ahmed N, et al. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol. 2009;113:143\u20138.","journal-title":"Gynecol Oncol."},{"key":"2878_CR17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/PAS.0b013e318033e7a8","volume":"31","author":"CE Comin","year":"2007","unstructured":"Comin CE, Saieva C, Messerini L. h-Caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139\u201348.","journal-title":"Am J Surg Pathol."},{"key":"2878_CR18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/modpathol.3800471","volume":"19","author":"NG Ordonez","year":"2006","unstructured":"Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006;19:34\u201348.","journal-title":"Mod Pathol."},{"key":"2878_CR19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ygyno.2006.12.033","volume":"105","author":"JM Estes","year":"2007","unstructured":"Estes JM, Oliver PG, Straughn JM Jr, et al. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol. 2007;105:291\u20138.","journal-title":"Gynecol Oncol."},{"key":"2878_CR20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/IGC.0b013e3181a2a003","volume":"19","author":"PJ Frederick","year":"2009","unstructured":"Frederick PJ, Kendrick JE, Straughn JM Jr, et al. Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. Int J Gynecol Cancer. 2009;19:814\u20139.","journal-title":"Int J Gynecol Cancer."},{"key":"2878_CR21","first-page":"69","volume-title":"Early detection of cancer: molecular markers","author":"WE Grizzle","year":"1997","unstructured":"Grizzle WE. Tissue resources in the detection and evaluation of markers. In: Srivastava S, editor. Early detection of cancer: molecular markers. Armonk: Futura Publishing Co., 1997:69\u201376."},{"key":"2878_CR22","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0002-9440(10)63058-1","volume":"159","author":"RC Casey","year":"2001","unstructured":"Casey RC, Burleson KM, Skubitz KM, et al. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol. 2001;159:2071\u201380.","journal-title":"Am J Pathol."},{"key":"2878_CR23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2003.12.034","volume":"93","author":"KM Burleson","year":"2004","unstructured":"Burleson KM, Casey RC, Skubitz KM, et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 2004;93:170\u201381.","journal-title":"Gynecol Oncol."},{"key":"2878_CR24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-5876-4-6","volume":"4","author":"KM Burleson","year":"2006","unstructured":"Burleson KM, Boente MP, Pambuccian SE, et al. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 2006;4:6.","journal-title":"J Transl Med."},{"key":"2878_CR25","first-page":"271","volume":"34","author":"WR Inch","year":"1970","unstructured":"Inch WR, McCredie JA, Sutherland RM. Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture. Growth. 1970;34:271\u201382.","journal-title":"Growth."},{"key":"2878_CR26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.2005.01.2757","volume":"24","author":"GJS Rustin","year":"2006","unstructured":"Rustin GJS, Timmers P, Nelstrop A, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the Intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol. 2006;24:45\u201351.","journal-title":"J Clin Oncol."},{"key":"2878_CR27","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/jnci\/djr282","volume":"103","author":"CK Lee","year":"2011","unstructured":"Lee CK, Friedlander M, Brown C, et al. Absence of early decline in CA125 is a poor surrogate for benefit of liposomal doxorubicin and carboplatin treatment in the CALYPSO study. J Natl Cancer Inst. 2011;103:1338\u201342.","journal-title":"J Natl Cancer Inst."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-2878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-013-2878-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-2878-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T11:22:56Z","timestamp":1559647376000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-013-2878-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,24]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2878"],"URL":"https:\/\/doi.org\/10.1245\/s10434-013-2878-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,24]]}}}